The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
Memorial Hermann's outreach sites will transfer testing to Quest's Houston lab and the firm will also provide management services for the system's 21 hospital labs.
Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.
Of the 39 deals included in the analysis, only three exceeded $100 million in value, with the rest having significantly smaller price tags or prices that were not disclosed.
The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019.
The new firm will offer target enrichment assays for clinical NGS testing and develop library preparation kits for clinical tests on Illumina's sequencing platform.
